App-Quantinova.ai

Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fc-receptor polymorphisms with survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO.

Holger N. Lode - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

ch14.18

Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): dose-finding and pharmacokinetics (PK).

Lucas Moreno - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Paclitaxel

Dose-finding study of vinblastine in combination with nilotinib in children, adolescents and young adults with refractory or recurrent low-grade glioma: Results of the ITCC/SIOPE-Brain VINILO phase I trial (NCT01887522).

Jacques / Grill - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Low-grade gliomas

Vinblastine

Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.

Holger N. Lode - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Interleukin

GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine/docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish Group of Sarcoma Investigation (GEIS).

Jaume Mora - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ewing's sarcoma

Gemcitabine

Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) StudyNCT01692496.

Claudia Maria Valverde - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liposarcomas

Pazopanib

Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-up of an exploratory analysis on a phase III trial.

Silvia Stacchiotti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Soft tissue sarcoma

Epirubicin

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

Elena Palassini - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Sarcoma

Epirubicin

CUL4A and ERCC1 genes as predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study.

Javier Martin Broto - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Sarcoma

Trabectedin

Trabectedin (T)-related liver toxicity: Results of a pharmacokinetic study with T in patients with hepatic dysfunction (OVC1004) and experience from a phase 3 clinical trial (SAR3007).

Emiliano Calvo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liposarcomas

Trabectedin

Tumor infiltrating lymphocytes before and after dual HER2 blockade in HER2-amplified early breast cancer: A TRYPHAENA substudy.

Michail Ignatiadis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Carboplatin

CHK1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients.

Daniela Morales-Espinosa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

TP53

Novel mutations in sporadic typical carcinoids of the lung (lung-TC): Tumor genomic profile by next generation sequencing (NGS).

Ivana GABRIELA Sullivan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Effect of Oncotype DX Recurrence Score (RS) on chemotherapy (CT) decision-making by providing information beyond intrinsic subtypes in both luminal A and B breast cancer (BC) patients (pts): A retrospective study in the Spanish population.

Laura Garcia-Estevez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Impact of Oncotype DX recurrence score in the management of pN1mic early breast cancer.

Patricia Novas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy.

Miguel Angel Segui-Palmer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Killer-cell Inmunoglobulin-like Receptor (KIR) genes as a predictor of response to the anti-HER therapy in solid tumors.

Cristina Morales-Estevez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Trastuzumab

The implementation of a multidisciplinary heredofamilial cancer unit to increase the referral and preventive surgeries of breast cancer patients with genetic risk in a university hospital.

Miriam Lobo de Mena - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Compliance and impact of screening on individuals at high risk of breast and ovarian cancer syndrome (BOCS).

Carmen Guillen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast and ovarian cancer syndrome

N/A

Cancer control in Latin America (LA) and the Caribbean: 2015 update.

Diego Touya - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

24923 Abstracts